Aprepitant (EMEND)

The role of substance P in nausea and vomiting

Eric Prommer

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalJournal of Pain and Palliative Care Pharmacotherapy
Volume19
Issue number3
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

aprepitant
Substance P
Nausea
Vomiting
Neurokinin-1 Receptor Antagonists
Neurokinin-1 Receptors
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Antagonist
  • Aprepitant
  • Nausea
  • Neurokinin
  • Review
  • Substance P
  • Vomiting

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Anesthesiology and Pain Medicine
  • Pharmacology (medical)

Cite this

Aprepitant (EMEND) : The role of substance P in nausea and vomiting. / Prommer, Eric.

In: Journal of Pain and Palliative Care Pharmacotherapy, Vol. 19, No. 3, 2005, p. 31-39.

Research output: Contribution to journalArticle

@article{a631efcfc4c843b896fc3f578a8493d1,
title = "Aprepitant (EMEND): The role of substance P in nausea and vomiting",
abstract = "Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.",
keywords = "Antagonist, Aprepitant, Nausea, Neurokinin, Review, Substance P, Vomiting",
author = "Eric Prommer",
year = "2005",
doi = "10.1300/J354v19n03_06",
language = "English (US)",
volume = "19",
pages = "31--39",
journal = "Journal of Pain and Palliative Care Pharmacotherapy",
issn = "1536-0288",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Aprepitant (EMEND)

T2 - The role of substance P in nausea and vomiting

AU - Prommer, Eric

PY - 2005

Y1 - 2005

N2 - Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.

AB - Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.

KW - Antagonist

KW - Aprepitant

KW - Nausea

KW - Neurokinin

KW - Review

KW - Substance P

KW - Vomiting

UR - http://www.scopus.com/inward/record.url?scp=27944434592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944434592&partnerID=8YFLogxK

U2 - 10.1300/J354v19n03_06

DO - 10.1300/J354v19n03_06

M3 - Article

VL - 19

SP - 31

EP - 39

JO - Journal of Pain and Palliative Care Pharmacotherapy

JF - Journal of Pain and Palliative Care Pharmacotherapy

SN - 1536-0288

IS - 3

ER -